Eidos Therapeutics Inc (NASDAQ:EIDX) has received an average broker rating score of 1.67 (Buy) from the three analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and two have assigned a strong buy rating to the company.

Brokerages have set a 1 year consensus target price of $29.67 for the company and are anticipating that the company will post ($0.35) EPS for the current quarter, according to Zacks. Zacks has also given Eidos Therapeutics an industry rank of 98 out of 255 based on the ratings given to its competitors.

A number of research firms recently issued reports on EIDX. Zacks Investment Research lowered Eidos Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday. JPMorgan Chase & Co. began coverage on Eidos Therapeutics in a research report on Monday, July 16th. They set an “overweight” rating and a $36.00 price objective for the company. Bank of America began coverage on Eidos Therapeutics in a research report on Monday, July 16th. They set a “neutral” rating and a $24.00 price objective for the company. Finally, Barclays began coverage on Eidos Therapeutics in a research report on Monday, July 16th. They set an “overweight” rating and a $32.00 price objective for the company.

In other Eidos Therapeutics news, CEO Neil Kumar purchased 1,000,000 shares of Eidos Therapeutics stock in a transaction on Friday, June 22nd. The stock was bought at an average price of $17.00 per share, for a total transaction of $17,000,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Rajeev M. Shah purchased 1,058,824 shares of Eidos Therapeutics stock in a transaction on Friday, June 22nd. The shares were acquired at an average price of $17.00 per share, with a total value of $18,000,008.00. The disclosure for this purchase can be found here.

Hedge funds have recently made changes to their positions in the business. Flinton Capital Management LLC acquired a new position in Eidos Therapeutics during the 2nd quarter worth $110,000. Point72 Hong Kong Ltd acquired a new position in Eidos Therapeutics during the 2nd quarter worth $111,000. Tiverton Asset Management LLC acquired a new position in Eidos Therapeutics during the 2nd quarter worth $163,000. Dean Capital Investments Management LLC acquired a new position in Eidos Therapeutics during the 2nd quarter worth $528,000. Finally, Citadel Advisors LLC acquired a new position in Eidos Therapeutics during the 2nd quarter worth $874,000. Institutional investors own 22.93% of the company’s stock.

NASDAQ:EIDX opened at $12.68 on Tuesday. Eidos Therapeutics has a 12-month low of $11.39 and a 12-month high of $24.75.

Eidos Therapeutics (NASDAQ:EIDX) last released its quarterly earnings data on Tuesday, August 7th. The company reported ($1.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($1.15). sell-side analysts anticipate that Eidos Therapeutics will post -2.09 earnings per share for the current fiscal year.

Eidos Therapeutics Company Profile

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

Read More: Moving Average – How it Helps Investors in Stock Selection

Get a free copy of the Zacks research report on Eidos Therapeutics (EIDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.